InvestSMART

Immuron Limited (ASX:IMC)

ALERT: Price-sensitive ASX Announcement for IMC
Current share price for IMC : $0.035 0.003 (9.38%)+
Announcement
Release
25 Feb 2026 4:42PM
Price at Release
$0.032
Full Release
download
Summary
Immuron Limited, a commercial-stage biopharmaceutical company, reported its HY26 results and strategic update, highlighting significant growth and developments. The company achieved a global sales revenue of AUD 4.2 million, marking a 5% increase compared to the previous year, with substantial gains in the Australian and U.S. markets. Immuron focuses on the development of oral antibody therapies using its proprietary 'Hyper-Immune' platform. Key products include Travelan® (IMM-124E) and IMM-529, both advancing in clinical trials with the U.S. FDA. Strategic partnerships are being pursued to fund these clinical programs. Despite a decline in North American sales due to Canadian market adjustments, the U.S. sales grew by 17% year-over-year. The company's financial health remains strong with AUD 10.0 million in cash reserves, enabling over 23 months of operational funding. Immuron's focus on high-barrier 'hyper-immune' products and partnerships aims to drive profitability and expand global reach.
Key Points
  • Global sales revenue of AUD 4.2 million, up 5% from the prior year.
  • Significant growth in Australian and U.S. markets, with U.S. sales increasing by 17% year-on-year.
  • Travelan® (IMM-124E) and IMM-529 advancing in FDA clinical trials.
  • Strategic partnerships pursued to fund clinical programs.
  • Financially stable with AUD 10.0 million in cash, supporting 23 months of operations.
  • North American sales decline due to market adjustments in Canada.
  • Focus on hyper-immune products and leveraging partnerships for profitability.
  • Expansion into one of Canada's largest pharmacy networks in Quebec to boost H2 FY26 revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.